Total Funding
4
8
Total FundingVenture - Series Unknown raised
Growth Score
0 pts
Heat Score
-46 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
551878
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.
Guy de Martynoff: Chief Technical Officer/Chief Manufacturing OfficerPast Role: DMS Biotechnology, Managing Director- David Béchard: Founder, President, CEO, and CSOPast Role: Endotis, Chairman / CEO
About the Company
Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer.
Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15
Cytune’s proprietary most advanced
proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector.
Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150.
Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)
